Epidemiology, outcomes, and the use of intensive care unit resources of critically ill patients diagnosed with COVID-19 in Sao Paulo, Brazil: A cohort study

Carregando...
Imagem de Miniatura
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
SOCOLOVITHC, Rachel Lane
FUMIS, Renata Rego Lins
TOMAZINI, Bruno Martins
PASTORE, Laerte
Citação
PLOS ONE, v.15, n.12, article ID e0243269, 13p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background The coronavirus disease (COVID-19) pandemic has brought significant challenges worldwide, with high mortality, increased use of hospital resources, and the collapse of healthcare systems. We aimed to describe the clinical outcomes of critically ill COVID-19 patients and assess the impact on the use of hospital resources and compare with critically ill medical patients without COVID-19. Methods and findings In this retrospective cohort study, we included patients diagnosed with COVID-19 admitted to a private ICU in Sao Paulo, Brazil from March to June 2020. We compared these patients with those admitted to the unit in the same period of the previous year. A total of 212 consecutive patients with a confirmed diagnosis of COVID-19 were compared with 185 medical patients from the previous year. Patients with COVID-19 were more frequently males (76% vs. 56%, p<0.001) and morbidly obese (7.5% vs. 2.2%, p = 0.027), and had lower SAPS 3 (49.65 (12.19) vs. 55.63 (11.94), p<0.001) and SOFA scores (3.78 (3.53) vs. 4.48 (3.11), p = 0.039). COVID-19 patients had a longer ICU stay (median of 7 vs. 3 days, p<0.001), longer duration of mechanical ventilation (median of 9 vs. 4 days, p = 0.003), and more frequent tracheostomies (10.8 vs. 1.1%, p<0.001). Survival rates until 28 days were not statistically different (91% vs. 85.4%, p = 0.111). After multivariable adjustment for age, gender, SAPS 3, and Charlson Comorbidity Index, COVID-19 remained not associated with survival at 28 days (HR 0.59, 95% CI 0.33-1.06, p = 0.076). Among patients who underwent invasive mechanical ventilation, the observed mortality at 28-days was 16.2% in COVID-19 patients compared to 34.6% in the previous year. Conclusions COVID-19 required more hospital resources, including invasive and non-invasive ventilation, had a longer duration of mechanical ventilation, and a more prolonged ICU and hospital length of stay. There was no difference in all-cause mortality at 28 and 60 days, suggesting that health systems preparedness be an important determinant of clinical outcomes.
Palavras-chave
Referências
  1. Armstrong RA, 2020, ANAESTHESIA, V75, P1340, DOI 10.1111/anae.15201
  2. Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
  3. Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
  4. Ferguson J, 2020, EMERG INFECT DIS, V26, P1679, DOI 10.3201/eid2608.201776
  5. Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
  6. Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
  7. Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
  8. Karagiannidis C, LANCET RESP MED
  9. Karagiannidis C, 2020, LANCET RESP MED, V8, P853, DOI 10.1016/S2213-2600(20)30316-7
  10. Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
  11. Mitra AR, 2020, CAN MED ASSOC J, V192, pE694, DOI 10.1503/cmaj.200794
  12. Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
  13. Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
  14. Ribeiro ALP, 2016, CIRCULATION, V133, P422, DOI 10.1161/CIRCULATIONAHA.114.008727
  15. Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.6775, 10.1001/jama.2020.7681]
  16. Saghazadeh A, 2020, EXPERT REV CLIN IMMU, V16, P465, DOI 10.1080/1744666X.2020.1750954
  17. Sanyaolu Adekunle, 2020, SN Compr Clin Med, P1, DOI 10.1007/s42399-020-00363-4
  18. Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE
  19. Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
  20. Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
  21. Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017